NNZ-2566 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome

Trial Timeline

Mar 1, 2016 → Jan 5, 2017

NCT ID

NCT02715115

About NNZ-2566 + Placebo

NNZ-2566 + Placebo is a phase 2 stage product being developed by Neuren Pharmaceuticals for Rett Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02715115. Target conditions include Rett Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02715115	Phase 2	Completed	Mar 1, 2016	Jan 5, 2017	Rett Syndrome
NCT02100150	Phase 2	Terminated	Sep 1, 2014	Jun 1, 2016	Concussion
NCT01894958	Phase 2	Completed	Jan 1, 2014	Oct 1, 2015	Fragile X Syndrome
NCT01703533	Phase 2	Completed	Mar 1, 2013	Sep 1, 2014	Rett Syndrome
NCT01366820	Phase 2	Completed	Feb 1, 2013	Jan 1, 2016	Brain Injuries
NCT01420042	Phase 1	Completed	Feb 1, 2012	Sep 1, 2012	Brain Injuries, Traumatic
NCT00805818	Phase 2	Completed	Apr 1, 2010	Jan 1, 2016	Brain Injuries
NCT00961779	Phase 1	Completed	Mar 1, 2010	Sep 1, 2010	Brain Injuries, Traumatic

Competing Products

20 competing products in Rett Syndrome

See all competitors

Product	Company	Stage	Hype Score
Esomeprazole + Aspirin + Rofecoxib	AstraZeneca	Approved	85
Esomeprazole + Lansoprazole	AstraZeneca	Approved	85
Esomeprazole Magnesium	AstraZeneca	Approved	85
AZD5213 and placebo	AstraZeneca	Phase 2	52
fingolimod (FTY720)	Novartis	Phase 1/2	41
PF-03654746 + Placebo + Placebo + PF-03654746	Pfizer	Phase 2	51
Aripiprazole	Bristol Myers Squibb	Pre-clinical	22
NBI-98854	Neurocrine Biosciences	Phase 2	49
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	49
Valbenazine	Neurocrine Biosciences	Phase 2	49
NBI-98854	Neurocrine Biosciences	Phase 1	30
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	49
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	49
Valbenazine	Neurocrine Biosciences	Phase 2	49
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	49
Abobotulinum toxin A	Ipsen	Pre-clinical	20
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	74
GWP42003-P	Jazz Pharmaceuticals	Phase 3	74
trofinetide	Acadia Pharmaceuticals	Phase 3	72
Trofinetide	Acadia Pharmaceuticals	Phase 3	72

Other Products from Neuren Pharmaceuticals

NNZ-2591 + PlaceboPhase 3

NNZ-2591Phase 2

NNZ-2566 + PlaceboPhase 2

NNZ-2591Phase 2